ClinicalTrials.gov
public full text
Public Domain
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
To evaluate the efficacy and safety of oral administration of dose-dependent EC-18 for 16 weeks in patients with moderate to severe atopic dermatitis
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis#844685
- Age differences in psychological comorbidity in atopic dermatitis: a systematic review and meta-analysis.#392656
- The Burden of Childhood Atopic Dermatitis in the Primary Care Setting: A Report from the Meta-LARC Consortium.#375498
- Moisturizer to Prevent Atopic Dermatitis#917013
- DIETARY FACTORS AND THEIR INFLUENCES ON ATOPIC DERMATITIS: INTEGRATING CROSS–SECTIONAL, LONGITUDINAL, AND RANDOMIZED CONTROLLED TRIAL APPROACHES#190571
Record · ID 884945
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive